Compass Therapeutics (CMPX) FCF Margin (2024)
Compass Therapeutics recorded quarterly FCF Margin of 1265.18% in Q2 2024.
Compass Therapeutics' FCF Margin history runs 1 years deep, the most recent figure standing at 1265.18% for Q2 2024.
- In Q2 2024, FCF Margin changed N/A year-over-year to 1265.18%; the TTM figure through Jun 2025 stood at 5331.18% (down 27976.0% YoY), while the FY2024 annual figure was 5282.24%, changed N/A from the prior year.
- FCF Margin came in at 1265.18% for Q2 2024 at Compass Therapeutics.
- In the past five years, FCF Margin ranged from a high of 1265.18% in Q2 2024 to a low of 1265.18% in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.17% |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -1,265.18% |